The Pharmacy and Poisons Board has approved the use of a prescription drug for the treatment of prostate cancer.
The drug, ZYTIGA (abiraterone acetate), is manufactured by Janssen, one of the pharmaceutical companies of Johnson & Johnson.
The local pharmacy regulator has approved the use of the once-daily medication for the treatment of metastatic castration-resistant prostate cancer ahead of a chemotherapy regime.
“The drug is only licensed for the treatment of advanced prostate cancer cases post-chemotherapy,” Janssen Kenya Country Manager Marseille Onyango said.
The ICC Champions Trophy 2025 could be moved to South Africa if the Pakistan CricketBoard (PCB) rejects the hybrid model,…
In addition to the Middle East and North Africa, the United Arab Emirates is becoming asignificant hub for trade and…
The UAE has established itself as a key player in the global aid regime, especially inAfrican countries. According to the…
President-elect Donald Trump on Thursday named Susie Wiles, a Florida strategist who ran his political operations for nearly four years,…
Zambia's untouched environment provides an unparalleled, up-close animal experience with a walking safari. Zambia's national parks including South Luangwa and…
The 29th session of the Conference of the Parties to the United Nations Framework Convention on Climate Change starts in…
This website uses cookies.